Skip to content

MacuLogix Announces Communication Guide for Eye Care Professionals

 

MIDDLETOWN, PA, June 27, 2017– MacuLogix, Inc., the only company to leverage the science of dark adaptation to help eliminate preventable blindness caused by age-related macular degeneration (AMD), today released a step-by-step communication guide for eye care professionals treating patients with AMD. MacuLogix collaborated with Laurie Sorrenson, OD, to develop its “12 Ways to Turn an AMD Diagnosis into News That’s Worth Celebrating” eBook, which is available online.

Being diagnosed with a chronic, progressive disease that can lead to blindness is often difficult for patients to comprehend. For many eye care professionals, it can also be particularly difficult to deliver this news to patients. Since the company’s AdaptDx® automated dark adaptometer enables eye care professionals to detect subclinical AMD three years earlier than it can be seen, MacuLogix published this eBook to help them deliver the diagnosis with confidence and improve long-term outcomes.

“How you deliver the message can make a significant difference in how a patient perceives it—and how they act on it. To that end, good communication skills can set you apart as a practitioner and have a major impact on patients’ lives,” said Laurie Sorrenson, OD, owner of Lakeline Vision Source in Cedar Park, TX. “Early diagnosis ought to be considered good news, but it can easily be misinterpreted as bad news, possibly resulting in less favorable outcomes.”

“12 Ways to Turn an AMD Diagnosis into News That’s Worth Celebrating” offers useful advice to help doctors improve delivery, with the goal of saving vision. It is available free of charge for download.

 

About MacuLogix

MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.